Potential Commercial Applications:
- Diagnostic biomarker of DHF
- Point-of-care diagnostic testing
- Enzyme-linked immunosorbent assay (ELISA) for clinical and laboratory use

Competitive Advantages:
- While there are commercially-available ELISAs to detect vitronectin, these products have not been used for dengue diagnosis
- Vitronectin assessment assays provide a novel, specific biomarker for the DHF disease state
- Easily developed for serologic diagnostic assays

Development Stage:
- Pre-clinical
- In vitro data available

Inventors: Elizabeth Hunsperger (CDC), Momar Ndai (McGill University), Kay Tomashek (CDC), Betty Poole-Smith (CDC)


Real-Time RT–PCR Assay for Detection of Noroviruses

Description of Technology: A specific and sensitive TaqMan-based real-time (rt) RT–PCR assay has been developed by CDC scientists for detection of noroviruses in clinical and environmental specimens. This assay can be implemented to rapidly detect and distinguish norovirus strains from genogroups I and II, which are responsible for the majority of human infections. Additionally, the assay is multiplexed with an internal extraction control virus (coliphage MS2) to validate the results of the assay. Since the virus cannot be grown in cell culture and enzyme immunoassays lack the necessary sensitivity, this technology is particularly useful.

Potential Commercial Applications:
- Development of norovirus diagnostics
- Specific rtRT–PCR assay for detecting and distinguishing of the major pathogenic norovirus genogroups (I and II) within clinical and environmental samples

Competitive Advantages:
- This is an internally controlled, multiplexed assay capable of rapid, accurate identification of norovirus genogroups responsible for human illness
- Superior sensitivity compared with immunoassay detection methods

Development Stage:
- Pre-clinical
- In vitro data available

Inventors: Jan Vinje, Nicole Gregoricus, Preeti Chhabra, Leslie Barclay, Hannah Shirley, David Lee (all of CDC)

Publications:

Real-Time RT–PCR Assay for Detection of Noroviruses

Description of Technology: A specific and sensitive TaqMan-based real-time (rt) RT–PCR assay has been developed by CDC scientists for detection of noroviruses in clinical and environmental specimens. This assay can be implemented to rapidly detect and distinguish norovirus strains from genogroups I and II, which are responsible for the majority of human infections. Additionally, the assay is multiplexed with an internal extraction control virus (coliphage MS2) to validate the results of the assay. Since the virus cannot be grown in cell culture and enzyme immunoassays lack the necessary sensitivity, this technology is particularly useful.

Potential Commercial Applications:
- Development of norovirus diagnostics
- Specific rtRT–PCR assay for detecting and distinguishing of the major pathogenic norovirus genogroups (I and II) within clinical and environmental samples

Competitive Advantages:
- This is an internally controlled, multiplexed assay capable of rapid, accurate identification of norovirus genogroups responsible for human illness
- Superior sensitivity compared with immunoassay detection methods

Development Stage:
- Pre-clinical
- In vitro data available

Inventors: Jan Vinje, Nicole Gregoricus, Preeti Chhabra, Leslie Barclay, Hannah Shirley, David Lee (all of CDC)

Publications:
Time: 10:00 a.m. to 11:30 a.m.  
Agenda: To review and evaluate grant applications.  
Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Sherry L. Dupere, Ph.D., Chief, Scientific Review Branch, Scientific Review Branch, National Institute of Child Health And Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–451–3415, dupere@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Alexander disease; Mechanisms, Modifiers and Therapeutics.

Date: February 7, 2014.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review Administrator, Scientific Review Branch, National Institute of Child Health and Human Development, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892–9004, (301) 456–6680, skandas@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Health, Behavior, and Context Subcommittee.

Date: February 17–18, 2014.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Michele C. Hindi-Alexander, Ph.D., Division of Scientific Review, National Institutes of Health, Eunice Kennedy Shriver National Institute for Child Health & Development, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892–7510, (301) 435–8382, hindialm@mail.nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Obstetrics and Maternal-Fetal Biology Subcommittee.

Date: March 5, 2014.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Peter Zelazowski, Ph.D., Scientific Review Officer, National Institutes of Health, NICHD, DSR, 6100 Executive Blvd., Bethesda, MD 20892, 301–435–6902, Peter.Zelazowski@nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Developmental Biology Subcommittee.

Date: February 27, 2014.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW., Washington, DC 20036.

Contact Person: Cathy J. Wedeen, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, 6100 Executive Blvd., Room 5B01–G, Bethesda, MD 20892, 301–435–6878, wedeen@nih.gov.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Reproduction, Andrology, and Gynecology Subcommittee.

Date: March 3, 2014.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Washington, DC/Rockville Hotel, Rockville, MD 20852.

Contact Person: Dennis E. Leszczynski, Ph.D., Scientific Review Administrator, Scientific Review Branch, National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892, (301) 435–2717, leszczyn@d.cm.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS).


Michelle Trout,  
Program Analyst, Office of Federal Advisory Committee Policy.  
[FR Doc. 2014–01630 Filed 1–28–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Alternative Medicine; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal or identifiable information of individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel; Interventional studies of non-pharmacological management of pain in military personnel (RO1, R34).

Date: March 31–April 1, 2014.

Time: 8:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Downtown Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Hungyi Shau, Ph.D., Scientific review officer, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, 301–402–1030, Hungyi.Shau@nih.gov.

Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel; Health Services and Observations of Non-Pharmacological Management of Pain In Military Personnel (RO1).

Date: April 1, 2014.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Downtown Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Hungyi Shau, Ph.D., Scientific Review Officer, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, 301–402–1030, Hungyi.Shau@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS).


Michelle Trout,  
Program Analyst, Office of Federal Advisory Committee Policy.  
[FR Doc. 2014–01633 Filed 1–28–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,